|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
WO2001045746A2
(en)
*
|
1999-12-24 |
2001-06-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
IL152656A0
(en)
|
2000-05-19 |
2003-06-24 |
Genentech Inc |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
JP2004538324A
(ja)
*
|
2001-08-03 |
2004-12-24 |
メディカル リサーチ カウンシル |
細胞内抗体
|
|
ES2401428T3
(es)
*
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
|
EP1716181B1
(en)
|
2004-02-19 |
2009-12-16 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
AU2005287404B2
(en)
*
|
2004-07-22 |
2009-05-07 |
Genentech, Inc. |
HER2 antibody composition
|
|
AU2005294347A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
|
BRPI0516577A
(pt)
*
|
2004-10-05 |
2008-09-16 |
Genentech Inc |
agentes terapêuticos com toxicidade diminuìda
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
MX2007008768A
(es)
|
2005-01-21 |
2007-10-19 |
Genentech Inc |
Dosificacion fija de anticuerpos her.
|
|
CN103251946A
(zh)
|
2005-02-23 |
2013-08-21 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
US8957187B2
(en)
*
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
MY150756A
(en)
|
2006-08-21 |
2014-02-28 |
Hoffmann La Roche |
Tumor theraphy with an anti-vegf antibody
|
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
|
AU2008234019B2
(en)
*
|
2007-04-03 |
2014-05-29 |
Amgen Research (Munich) Gmbh |
Cross-species-specific bispecific binders
|
|
PT2155783E
(pt)
†
|
2007-04-03 |
2013-11-07 |
Amgen Res Munich Gmbh |
Domínio de ligação específico inter-espécies
|
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
|
WO2008150485A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Wyeth |
Erbb2 binding proteins and use thereof
|
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
SG10201507044PA
(en)
|
2009-05-29 |
2015-10-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
WO2011084496A1
(en)
*
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
CN102167742B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
CA2818635C
(en)
|
2010-12-06 |
2021-06-15 |
National Reseach Council Of Canada |
Antibodies selective for cells presenting erbb2 at high density
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
DK4403228T3
(da)
|
2011-10-14 |
2025-10-13 |
Hoffmann La Roche |
Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
SG11201402510TA
(en)
|
2011-11-30 |
2014-06-27 |
Genentech Inc |
Erbb3 mutations in cancer
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
US20150079093A1
(en)
*
|
2012-01-13 |
2015-03-19 |
Julus-Maximilians-Universität Würzburg |
Dual antigen-induced bipartite functional complementation
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
KR101505157B1
(ko)
*
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
US9777067B2
(en)
|
2012-09-27 |
2017-10-03 |
Massachusetts Institute Of Technology |
HER2- and VEGF-A-binding proteins with enhanced stability
|
|
HUE045435T2
(hu)
|
2012-10-12 |
2019-12-30 |
Medimmune Ltd |
Pirrolobenzodiazepinek és konjugátumaik
|
|
KR20210090298A
(ko)
|
2012-10-30 |
2021-07-19 |
에스퍼란스 파마슈티컬스, 인코포레이티드 |
항체/약물 컨쥬게이트 및 이의 사용 방법
|
|
BR112015012644A2
(pt)
|
2012-11-30 |
2017-12-19 |
Hoffmann La Roche |
método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
|
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びその結合体
|
|
JP6433085B2
(ja)
|
2013-04-09 |
2018-12-05 |
ボストン バイオメディカル， インコーポレイテッド |
がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
|
|
RU2737727C2
(ru)
|
2013-04-16 |
2020-12-02 |
Дженентек, Инк. |
Варианты пертузумаба и их аналитическая характеристика
|
|
WO2014182970A1
(en)
*
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
KR102357961B1
(ko)
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
JP6510532B2
(ja)
|
2013-12-20 |
2019-05-08 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｈｅｒ２抗体及び使用方法
|
|
ES2723774T3
(es)
|
2014-03-11 |
2019-09-02 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
|
SI3604333T1
(sl)
|
2014-03-11 |
2021-08-31 |
Molecular Templates, Inc. |
Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
|
|
EP3129055B1
(en)
*
|
2014-04-11 |
2020-07-01 |
MedImmune, LLC |
Bispecific her2 antibodies
|
|
RU2020120593A
(ru)
|
2014-04-25 |
2020-09-01 |
Дженентек, Инк. |
Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
CN105985435B
(zh)
*
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
ES2984592T3
(es)
|
2015-05-30 |
2024-10-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2
|
|
EA201792623A1
(ru)
|
2015-06-03 |
2018-04-30 |
Бостон Биомедикал, Инк. |
Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
|
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107787331B
(zh)
*
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
EP3534948A1
(en)
|
2016-11-04 |
2019-09-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
AU2017387909A1
(en)
|
2016-12-28 |
2019-06-27 |
Genentech, Inc. |
Treatment of advanced HER2 expressing cancer
|
|
TW202508629A
(zh)
|
2017-01-17 |
2025-03-01 |
美商建南德克公司 |
皮下her2抗體調配物
|
|
AU2018213194B2
(en)
|
2017-01-25 |
2023-01-12 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
|
|
KR20230144110A
(ko)
|
2017-03-02 |
2023-10-13 |
제넨테크, 인크. |
Her2-양성 유방암 어쥬번트 치료
|
|
JP7473339B2
(ja)
*
|
2017-03-07 |
2024-04-23 |
エフ． ホフマン－ラ ロシュ アーゲー |
代替の抗原特異的抗体変異体を発見するための方法
|
|
KR20190140952A
(ko)
|
2017-04-24 |
2019-12-20 |
제넨테크, 인크. |
막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
NZ762376A
(en)
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
MX2020008289A
(es)
*
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
|
CA3097178A1
(en)
|
2018-04-17 |
2019-10-24 |
Molecular Templates, Inc. |
Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP7644978B2
(ja)
*
|
2019-02-03 |
2025-03-13 |
上海宝済薬業股▲ふん▼有限公司 |
Ｈｅｒ２に対する二重特異性抗体及びその応用
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
TW202140559A
(zh)
*
|
2020-01-23 |
2021-11-01 |
美商拜奧亞特拉公司 |
條件性活性抗ｈｅｒ２抗體，抗體片段、其免疫結合物及其用途
|
|
JP7737996B2
(ja)
*
|
2020-01-23 |
2025-09-11 |
エクスマ バイオテック コーポレイション |
Ｈｅｒ２に対するキメラ抗原受容体およびその使用方法
|
|
TWI867218B
(zh)
*
|
2020-04-30 |
2024-12-21 |
大陸商正大天晴藥業集團股份有限公司 |
靶向her2的抗原結合建構體及用途
|
|
JP2023532122A
(ja)
|
2020-06-29 |
2023-07-26 |
ジェネンテック， インコーポレイテッド |
ペルツズマブにトラスツズマブを加えた固定用量配合剤
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
PE20231512A1
(es)
|
2020-10-25 |
2023-09-26 |
Araris Biotech Ag |
Medios y metodos para producir conjugados de ligador-anticuerpo
|
|
IL303350A
(en)
|
2020-12-04 |
2023-08-01 |
Macrogenics Inc |
Pharmaceutical compositions of a her2/neu antibody and use of the same
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
CA3236930A1
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
MA71625A
(fr)
|
2022-07-30 |
2025-05-30 |
Pinetree Therapeutics, Inc. |
Compositions pour la dégradation lysosomale ciblée et leurs procédés d'utilisation
|
|
KR20250068754A
(ko)
*
|
2022-09-20 |
2025-05-16 |
바이오세우스 인크. |
항-her2 항체 및 이의 용도
|
|
TW202434307A
(zh)
|
2023-01-18 |
2024-09-01 |
大陸商泰勵生物科技（上海）有限公司 |
抗體偶聯藥物及其用途
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|